Allogene Therapeutics, Inc. (ALLO)
NASDAQ: ALLO · Real-Time Price · USD
2.300
+0.020 (0.88%)
At close: May 12, 2026, 4:00 PM EDT
2.314
+0.014 (0.62%)
After-hours: May 12, 2026, 7:58 PM EDT
Allogene Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
152
Market Cap
793.56M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 22.00K | -73.00K | -76.84% |
| Dec 31, 2023 | 95.00K | -61.00K | -39.10% |
| Dec 31, 2022 | 156.00K | -113.93M | -99.86% |
| Dec 31, 2021 | 114.09M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Theravance Biopharma | 109.78M |
| Kura Oncology | 67.48M |
| CytomX Therapeutics | 35.54M |
| Evommune | 10.00M |
| Odyssey Therapeutics | 2.98M |
ALLO News
- 6 days ago - Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update - GlobeNewsWire
- 21 days ago - Allogene Therapeutics expands Phase 2 ALPHA3 trial to South Korea, Australia - TheFly
- 21 days ago - Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia - GlobeNewsWire
- 22 days ago - Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026 - GlobeNewsWire
- 26 days ago - Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock - GlobeNewsWire
- 26 days ago - Allogene Therapeutics price target lowered to $11 from $12 at H.C. Wainwright - TheFly
- 26 days ago - Allogene Therapeutics upgraded to Neutral from Underweight at JPMorgan - TheFly
- 27 days ago - Allogene Therapeutics price target raised to $10 from $6 at Jefferies - TheFly